Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Herman

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Leukemia|April 27, 2013
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyS E M Herman, X Sun, E M McAuley, et al.
Blood Advances|March 31, 2022
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemiaClare Sun, Yun-Ching Chen, Aina Martinez Zurita, et al.
Blood|November 21, 2012
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBo Yu, Yicheng Mao, Li-Yuan Bai, et al.
Cancer Research|October 11, 2017
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic LeukemiaNakhle S Saba, Deanna H Wong, Georges Tanios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination TherapyMartin Skarzynski, Carsten U Niemann, Yuh Shan Lee, et al.
Leukemia|July 20, 2016
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemiaL M Saleh, W Wang, S E M Herman, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Blood|June 5, 2010
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsSarah E M Herman, Amber L Gordon, Amy J Wagner, et al.
Blood|October 21, 2010
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBrian J Lannutti, Sarah A Meadows, Sarah E M Herman, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Blood|May 11, 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib eraHannah R Robinson, Junpeng Qi, Erika M Cook, et al.
Leukemia|April 27, 2013
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyS E M Herman, X Sun, E M McAuley, et al.
Blood Advances|March 31, 2022
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemiaClare Sun, Yun-Ching Chen, Aina Martinez Zurita, et al.
Blood|November 21, 2012
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBo Yu, Yicheng Mao, Li-Yuan Bai, et al.
Cancer Research|October 11, 2017
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic LeukemiaNakhle S Saba, Deanna H Wong, Georges Tanios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination TherapyMartin Skarzynski, Carsten U Niemann, Yuh Shan Lee, et al.
Leukemia|July 20, 2016
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemiaL M Saleh, W Wang, S E M Herman, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Blood|June 5, 2010
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsSarah E M Herman, Amber L Gordon, Amy J Wagner, et al.
Blood|October 21, 2010
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBrian J Lannutti, Sarah A Meadows, Sarah E M Herman, et al.
Pageof 10